The global challenge posed by HIV-1 infection continues to drive research into its underlying mechanisms and the host immune response. Central to this pursuit is the role of T cells, particularly CD4 ...

Immunocore’s big swing for a functional HIV cure has cleared its first hurdle. No serious adverse events were tied to the British biotech’s bispecific T-cell engager in a phase 1/2 trial, and the ...

A new study has overcome a long-standing challenge: how to isolate and study elusive HIV-infected cells called authentic reservoir clones (ARCs) that evade the immune system, making the disease ...

At the cellular level, HIV-1 transmission involves a highly coordinated process whereby the virus binds to CD4 receptors and one of two coreceptors—CCR5 (R5) or CXCR4 (X4)—on host immune cells, ...

Advancements in HIV/AIDS research, drug development and clinical practice since the 1980s have made it possible for people living with HIV to lead long, productive lives and keep the virus in check at ...

Advancements in HIV/AIDS research, drug development, and clinical practice since the 1980s have made it possible for people living with HIV to lead long, productive lives and keep the virus in check ...

Led by a team of African researchers, first doses of the novel T cell-inducing GRAdHIVNE1 vaccine candidate have been given. HARARE, ZIMBABWE, ROME, ITALY, NEW YORK, NY, AND CAMBRIDGE, MA / ACCESS ...

Despite the capability of antiretroviral drugs to suppress HIV to undetectable levels, some people living with the human immunodeficiency virus can't reach the goal of viral imperceptibility even with ...

– New grant from the Bill & Melinda Gates Foundation supports the Phase 1 development of VIR-1388, an investigational HIV T cell vaccine based on a novel vector – – Long-standing partnership further ...